Clinical Research Informer

Cancer Research UK and CRIS fund lung cancer vaccine research

Pharmaceutical Technology

MARCH 25, 2024

Cancer Research UK and the CRIS Cancer Foundation have awarded a £1.7m ($2.1m) grant for developing the lung cancer vaccine LungVax.

Vaccination

Vaccination Vaccine Research Development

Health Canada approves Merck’s KEYTRUDA for gastric cancer treatment

Pharmaceutical Technology

APRIL 22, 2024

Health Canada has approved Merck’s KEYTRUDA (pembrolizumab), an anti-programmed cell death protein 1 (PD-1) therapy for use in combination with fluoropyrimidine- and platinum-containing-chemotherapy as a first-line treatment for adult gastric cancer patients.

Containment

Containment Protein

Datopotamab deruxtecan by Daiichi Sankyo for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval

Pharmaceutical Technology

APRIL 22, 2024

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).

Clinical Development

Clinical Development Development

Breaking barriers: Advances and challenges in therapeutic cancer vaccines

Bio Pharma Dive

APRIL 1, 2024

The development of cancer vaccines has provided some hope in the battle against cancer worldwide; however, there are still many challenges to overcome when developing these life-saving treatments.

Vaccination

Vaccination Vaccine Development

India’s Tata Institute develops tablet for cancer recurrence prevention

Pharmaceutical Technology

FEBRUARY 29, 2024

India’s Tata Institute has developed a tablet combining resveratrol and copper that has the potential to prevent the recurrence of cancer.

Development

Novartis pauses some trials of cancer drug Kisqali to fix manufacturing

Bio Pharma Dive

APRIL 10, 2024

The company said the pause is necessary to meet regulatory limits on nitrosamine, but added it will not affect commercial supply nor regulatory review of the drug in early breast cancer.

Manufacturing

Manufacturing Drugs Trials

Merck puts KRAS cancer drug competitor to the test

Bio Pharma Dive

APRIL 4, 2024

A Phase 3 study will compare Merck’s experimental KRAS inhibitor together with its immunotherapy Keytruda against Keytruda alone in lung cancer.

Drugs

AST-001 by Ascentawits Pharmaceuticals for Rectal Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 22, 2024

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Rectal Cancer.

Clinical Development

Clinical Development Development

AST-001 by Ascentawits Pharmaceuticals for Esophageal Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 22, 2024

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Esophageal Cancer.

Clinical Development

Clinical Development Development

AST-001 by Ascentawits Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 22, 2024

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer.

Clinical Development

Clinical Development Development

Clasp launches with $150M and a plan for precision cancer immunotherapies

Bio Pharma Dive

MARCH 20, 2024

The company claims its approach could yield more effective and safer T-cell engagers, a type of cancer medicine that’s attracted significant interest from drugmakers in recent years.

Medicine

UK NHS introduces new endometrial cancer immunotherapy

Pharmaceutical Technology

MARCH 5, 2024

The UK NHS has introduced the new checkpoint inhibitor immunotherapy dostarlimab (Jemperli) for women with advanced endometrial cancer.

NIH team develops AI tool to predict cancer drug response

Pharmaceutical Technology

APRIL 19, 2024

Researchers at the National Cancer Institute, a unit of the National Institutes of Health (NIH) in the US, have developed an AI tool that can predict drug responses in cancer treatment.

Development

Development Drugs Research

ImmunityBio’s ANKTIVA receives FDA approval for bladder cancer

Pharmaceutical Technology

APRIL 23, 2024

The US Food and Drug Administration (FDA) has granted approval for ImmunityBio's ANKTIVA, plus Bacillus Calmette-Guérin (BCG), for treating patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

FDA Approval

FDA Approval Drugs

Farletuzumab ecteribulin by Eisai for Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 22, 2024

Farletuzumab ecteribulin is under clinical development by Eisai and currently in Phase II for Ovarian Cancer.

Clinical Development

Clinical Development Development

BioNTech’s RNA vaccine sparks potential in pancreatic cancer

Pharmaceutical Technology

MAY 11, 2023

Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.

RNA

RNA Vaccination Vaccine Trials

Datopotamab deruxtecan by Daiichi Sankyo for Epithelial Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 22, 2024

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Epithelial Ovarian Cancer.

Clinical Development

Clinical Development Development

Datopotamab deruxtecan by Daiichi Sankyo for Metastatic Ovarian Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 22, 2024

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Ovarian Cancer.

Clinical Development

Clinical Development Development

Targeting mouth cancer with light-activated drugs

Pharmaceutical Technology

APRIL 23, 2024

LightOx explained how light-activated drugs can be used to treat cancer on day one of the Biotrinity 2024 conference in London.

Drugs

Cancer UK partners with Guardant to advance cancer drugs and diagnostics

Pharmaceutical Technology

DECEMBER 4, 2023

The agreement allows Guardant Health to leverage Cancer Research UK’s network to validate its technologies.

Drugs

Drugs Research

Accent Therapeutics secures funding to advance cancer therapies

Pharmaceutical Technology

JANUARY 24, 2024

Accent Therapeutics has raised $75m in a Series C financing round to progress the development of precision cancer therapies.

Development

Boehringer and CBmed partner to develop cancer therapies

Pharmaceutical Technology

FEBRUARY 9, 2024

Boehringer has entered a strategic collaboration with CBmed to expedite the translation of cancer treatment approaches into new therapies.

Development

California Man Free of HIV And Cancer in Astonishing Medical Recovery

AuroBlog - Aurous Healthcare Clinical Trials blog

FEBRUARY 27, 2024

On the list of illnesses that nobody wants, cancer and HIV both rank pretty high, and Californian man Paul Edmonds had both. But ever since one particular treatment five years ago, he’s been free of both cancer and HIV.

Clinical Trials

Clinical Trials Clinical Trials Trials

EMA awards double validation for Daiichi Sankyo and AstraZeneca’s cancer ADC

Pharmaceutical Technology

MARCH 4, 2024

The EMA has validated the jointly developed TROP2-directed therapy for patients with breast or lung cancer following positive Phase III data.

Development

PRO-1107 by ProfoundBio Suzhou for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

Pharmaceutical Technology

APRIL 19, 2024

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer).

Clinical Development

Clinical Development Development

2023 in review: Cancer vaccines dose up on advances with tailored approaches

Pharmaceutical Technology

DECEMBER 22, 2023

As the number of patients with cancers continues to grow globally, research into personalised cancer vaccines is vital.

Vaccination

Vaccination Vaccine Research

UK NICE recommends Pfizer’s talazoparib for advanced breast cancer

Pharmaceutical Technology

JANUARY 22, 2024

The UK NICE recommends Pfizer's talazoparib, marketed as Talzenna, to treat a specific type of locally advanced or metastatic breast cancer.

Marketing

Hyundai to advance cancer study plans for niclosamide-based drug

Pharmaceutical Technology

APRIL 22, 2024

The niclosamide-based candidate has been repurposed as a cancer treatment by Hyundai and CNPharm after being originally developed for Covid-19.

Drugs

Drugs Development

AstraZeneca’s durvalumab recommended for bile duct cancers

Pharmaceutical Technology

DECEMBER 1, 2023

The SMC and NICE have recommended the use of AstraZeneca’s durvalumab to treat advanced biliary tract cancers in England and Scotland.

Prothea debuts with $13m to develop cancer diagnostics and treatment

Pharmaceutical Technology

APRIL 9, 2024

Prothea plans to use the funds to start clinical trial for cancer imaging, biopsy and laser ablation treatment in lung cancer patients.

Clinical Trials

Clinical Trials Clinical Trials Development Trials

Lisata receives orphan drug designation for pancreatic cancer therapy

Pharmaceutical Technology

OCTOBER 18, 2023

Lisata has received orphan drug designation from the EMA's Committee for Orphan Medicinal Products for LSTA1 to treat pancreatic cancer.

Drugs

Drugs Medicine Production

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Pharma Times

APRIL 19, 2024

Both will develop cancer vaccine candidates in selected haematological and solid tumour indications

Vaccination

Vaccination Vaccine Development

Novartis signs deal for Arvinas’ prostate cancer therapy

Pharmaceutical Technology

APRIL 12, 2024

Novartis has signed an exclusive strategic licence agreement for Arvinas’ ARV-766, a new treatment for prostate cancer.

Study suggests tumour microenvironments could predict cancer progression

Pharma Times

APRIL 12, 2024

NSCLC is the most common type of lung cancer and is responsible for up to 85% of all cases

Research

AACR, Cancer Treatment and the Promise of Antibody-Drug Conjugates

BioSpace

APRIL 12, 2024

This week’s American Association for Cancer Research annual meeting drove home the importance of antibody-drug conjugates as an emerging class of potential anti-cancer therapeutics.

Antibody

Antibody Drugs Research

AFNT-211 by Affini-T Therapeutics for Colorectal Cancer: Likelihood of Approval

Pharmaceutical Technology

APRIL 22, 2024

AFNT-211 is under clinical development by Affini-T Therapeutics and currently in Phase II for Colorectal Cancer.

Clinical Development

Clinical Development Development

DX-126262 by Hangzhou DAC Biotech for Breast Cancer: Likelihood of Approval

Pharmaceutical Technology

FEBRUARY 8, 2024

DX-126262 is under clinical development by Hangzhou DAC Biotech and currently in Phase I for Breast Cancer.

Clinical Development

Clinical Development Development

Research uncovers how to target dormant breast cancer cells

Drug Discovery World

MARCH 27, 2024

Scientists have discovered how breast cancer cells can ‘hibernate’ to avoid treatment and ‘wake up’ years later – causing a relapse that is more difficult to treat. To reduce their risk of relapse, patients undergo five to ten years of hormone therapy to target any remaining cancer cells.

Research

Research Hormones Regulation Scientist

Vaccines, Next-Gen Approaches Target the Toughest Cancers: AACR

BioSpace

APRIL 11, 2024

Data presented the American Association for Cancer Research’s annual meeting sparked hope that we could be getting closer to treating pancreatic cancer, glioblastoma and other particularly difficult tumors.

Vaccination

Vaccination Vaccine

FDA clears ImmunityBio’s bladder cancer drug at 2nd attempt

pharmaphorum

APRIL 23, 2024

After rejecting ImmunityBio’s Anktiva last year, the FDA has now cleared the drug as a treatment for bladder cancer, making it the biotech's first commercial-stage product

Drugs

Drugs Production

ADRIATIC buoys Imfinzi’s prospects in early lung cancer

pharmaphorum

APRIL 5, 2024

ADRIATIC trial finds AstraZeneca's cancer immunotherapy Imfinzi improves survival in patients with limited-stage small cell lung cancer (SCLC)

Trials

AACR 2024: What Cancer Researchers Are Talking About

BioSpace

APRIL 5, 2024

The American Association for Cancer Research (AACR)’s annual conference runs April 5 through April 10. BioSpace will have all the key data and news out of San Diego.

Research

Bio-Rad and Alleghany Health Network partner for patients with solid tumour cancer

Pharma Times

APRIL 10, 2024

Solid tumour cancers account for 90% of adult human cancers and 50% of childhood malignancies

‘Stiffness’ of cells could give early warning of cancer

pharmaphorum

APRIL 16, 2024

Researchers from the UK have developed an endoscopic device that uses 3D imaging to look at the stiffness of cells and could diagnose cancer earlier.

Development

Development Research

Cancer Research UK and CRIS fund lung cancer vaccine research

Health Canada approves Merck’s KEYTRUDA for gastric cancer treatment

Trending Sources

Datopotamab deruxtecan by Daiichi Sankyo for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval

Breaking barriers: Advances and challenges in therapeutic cancer vaccines

India’s Tata Institute develops tablet for cancer recurrence prevention

Novartis pauses some trials of cancer drug Kisqali to fix manufacturing

Merck puts KRAS cancer drug competitor to the test

AST-001 by Ascentawits Pharmaceuticals for Rectal Cancer: Likelihood of Approval

AST-001 by Ascentawits Pharmaceuticals for Esophageal Cancer: Likelihood of Approval

AST-001 by Ascentawits Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval

Clasp launches with $150M and a plan for precision cancer immunotherapies

UK NHS introduces new endometrial cancer immunotherapy

NIH team develops AI tool to predict cancer drug response

ImmunityBio’s ANKTIVA receives FDA approval for bladder cancer

Farletuzumab ecteribulin by Eisai for Ovarian Cancer: Likelihood of Approval

BioNTech’s RNA vaccine sparks potential in pancreatic cancer

Datopotamab deruxtecan by Daiichi Sankyo for Epithelial Ovarian Cancer: Likelihood of Approval

Datopotamab deruxtecan by Daiichi Sankyo for Metastatic Ovarian Cancer: Likelihood of Approval

Targeting mouth cancer with light-activated drugs

Cancer UK partners with Guardant to advance cancer drugs and diagnostics

Accent Therapeutics secures funding to advance cancer therapies

Boehringer and CBmed partner to develop cancer therapies

California Man Free of HIV And Cancer in Astonishing Medical Recovery

EMA awards double validation for Daiichi Sankyo and AstraZeneca’s cancer ADC

PRO-1107 by ProfoundBio Suzhou for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

2023 in review: Cancer vaccines dose up on advances with tailored approaches

UK NICE recommends Pfizer’s talazoparib for advanced breast cancer

Hyundai to advance cancer study plans for niclosamide-based drug

AstraZeneca’s durvalumab recommended for bile duct cancers

Prothea debuts with $13m to develop cancer diagnostics and treatment

Lisata receives orphan drug designation for pancreatic cancer therapy

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Novartis signs deal for Arvinas’ prostate cancer therapy

Study suggests tumour microenvironments could predict cancer progression

AACR, Cancer Treatment and the Promise of Antibody-Drug Conjugates

AFNT-211 by Affini-T Therapeutics for Colorectal Cancer: Likelihood of Approval

DX-126262 by Hangzhou DAC Biotech for Breast Cancer: Likelihood of Approval

Research uncovers how to target dormant breast cancer cells

Vaccines, Next-Gen Approaches Target the Toughest Cancers: AACR

FDA clears ImmunityBio’s bladder cancer drug at 2nd attempt

ADRIATIC buoys Imfinzi’s prospects in early lung cancer

AACR 2024: What Cancer Researchers Are Talking About

Bio-Rad and Alleghany Health Network partner for patients with solid tumour cancer

‘Stiffness’ of cells could give early warning of cancer

Stay Connected